April 20, 2018 5:12 PM ET

Life Sciences Tools and Services

Company Overview of Advinus Therapeutics Ltd.

Company Overview

Advinus Therapeutics Ltd. provides drug discovery, and pharmaceutical and agrochemical development services in India. The company’s drug discovery services include developing small molecule therapies for indications in metabolic diseases, such as diabetes and obesity; inflammatory diseases, including chronic obstructive pulmonary diseases, inflammatory bowel diseases, and autoimmune disorders; pain/degenerative diseases, which comprise Parkinson’s diseases; and neglected diseases, such as leishmaniasis, dengue fever, tuberculosis, leprosy, and malaria. Its pharmaceutical development services include process development and synthesis, process chemistry, pre-formulation, drug metabolism and ph...

No 21 & No 22 Phase II

Peenya Industrial Area

Bengaluru,  560058


Founded in 2005


91 80 2839 4959


91 80 2839 4015

Key Executives for Advinus Therapeutics Ltd.

Chief Scientific Officer and Executive Vice President of Drug Discovery
Senior Vice President and Head of Pharmaceuticals & Agrochemical Development
Head of Corporate Quality Assurance and Vice President
Compensation as of Fiscal Year 2017.

Advinus Therapeutics Ltd. Key Developments

Tata Sons Is Reported To Sell Advinus Therapeutics

Tata Sons Limited (Tata Group) is reviewing its diverse portfolio to streamline operations and allocate capital more efficiently. Sources said the group has started a process to sell Advinus Therapeutics Ltd., drawing interest from Kedaara Capital Investment Managers Limited and True North Venture Partners, L.P., as well as from strategic players, GVK Biosciences Private Limited and Lambda Therapeutic Research Ltd.

Advinus Therapeutics Ltd. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

Advinus Therapeutics Ltd. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, California, United States.

Idogen Signs Agreement with Advinus Therapeutics Ltd for Synthesis of Zebularine

Idogen AB announced that the company has signed an agreement with Advinus Therapeutics, for synthesis of zebularine for future pre-clinical and clinical trials. Zebularine is a key component in Idogen’s tolerogenic vaccine. The agreement means that zebularine will be synthesized according to current regulations for GMP. This represents an important step taken by Idogen towards a product for clinical trials.

Recent Private Companies Transactions

July 20, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Advinus Therapeutics Ltd., please visit www.advinus.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.